Skip to main content

Urine Studies

Urinalysis, culture, cytology, prostatitis-localization tests, and 24-hour collections answer different clinical questions. Interpret each result alongside symptoms, specimen quality, anatomy, catheter use, and prior microbiology. Bacteriuria in a bowel-based diversion or catheterized bladder is common and does not, by itself, diagnose infection; new compatible symptoms still warrant assessment and an appropriately collected culture.[1][3][12]​

Specimen Collection​

  • Voided specimens: use instructed midstream collection for bacterial culture. First-void urine is used for selected STI nucleic-acid tests; follow that test's collection instructions rather than substituting midstream urine.[1][2]
  • Straight catheterization: useful when repeated voided specimens are contaminated or reliable collection is not possible. AUA 2025 advises repeat studies when a specimen is suspect for contamination, with consideration of a catheterized specimen; AUGS 2025 states that straight catheterization should be performed when vaginal or skin contamination is suspected or anatomy prevents a clean catch (wheelchair use, significant prolapse, morbid obesity).[29][43] Balance improved specimen quality against instrumentation discomfort and risk.[1][29][43]
  • Indwelling catheters: avoid drainage-bag or catheter-tip cultures. Obtain urine aseptically from the sampling port; when an established catheter is changed for suspected infection, obtain the specimen from the new catheter. The AUA/SUFU NLUTD guideline specifies collection after the catheter is changed and urine has accumulated with the catheter plugged, and not from the extension tubing or collection bag.[1][23]
  • Diversions and nephrostomies: avoid routine cultures in asymptomatic patients. When infection is suspected, collect from an appropriate fresh specimen or device sampling site according to the reconstruction and local protocol, rather than an old collection bag. Colonization complicates interpretation of clinically indicated cultures.[1][21]
  • Suprapubic aspiration: a selective invasive collection method, not a routine first choice. Laboratories commonly culture to 1,000 CFU/mL; lower counts may matter in context and should be discussed with the laboratory.[1]
  • Transport: send promptly. The 2024 IDSA/ASM guidance recommends refrigeration if urine cannot be processed within 30 minutes; use the laboratory's validated preservative and transport protocol when delayed.[1] Prolonged room-temperature storage can cause misleading bacterial overgrowth.[1][2]
  • Squamous epithelial cells: may suggest contamination. Repeat an uninterpretable specimen with improved collection technique.[3]

Dipstick Urinalysis​

  • Leukocyte esterase: indicates leukocytes and inflammation, which may be infectious or noninfectious.[4][5][6]
  • Nitrites: support bacteriuria with nitrate-reducing organisms. A negative result does not exclude infection: frequent voiding and organisms such as Enterococcus can produce false-negative results.[1][4][5]
  • Blood: confirm by microscopy before diagnosing microhematuria. Hemoglobin or myoglobin can produce a positive dipstick without intact RBCs; very dilute urine can lyse RBCs and lower the microscopic count.[7][9]
  • pH: low pH favors uric-acid crystallization; persistently alkaline urine may reflect urease-producing infection, calcium-phosphate stone risk, or impaired urinary acidification.[8][38]
  • Protein: confirm persistent proteinuria with quantitative testing, usually a urine albumin/creatinine ratio, and assess renal context.[4]

Microscopic Urinalysis​

Microscopy complements dipstick testing; neither is uniformly more sensitive for every finding.

  • RBCs: ≥3 RBCs/HPF in a properly collected specimen defines microhematuria under AUA/SUFU guidance. Dysmorphic RBCs and RBC casts suggest glomerular disease.[7][9] Isomorphic RBCs can arise from nonglomerular bleeding anywhere in the urinary tract.[7][9]
  • WBCs: pyuria supports urinary inflammation. Absence of pyuria makes acute bacterial cystitis less likely in the usual non-neutropenic outpatient population but cannot exclude it in complicated anatomy, neutropenia, or other special circumstances.[1][6][29]
  • Bacteria: indicate bacteriuria, contamination, or infection depending on collection quality and symptoms.[1][3]
  • Crystals: morphology can guide further investigation. Hexagonal cystine crystals are highly suggestive of cystinuria; struvite-like or calcium-oxalate crystals need interpretation with urine chemistry and, when available, formal stone analysis.[10][11][38]
  • Casts: RBC casts suggest glomerular bleeding; WBC casts can occur with pyelonephritis or interstitial nephritis.[4][7]

Urine Culture: Thresholds and Interpretation​

There is no colony-count cutoff that independently diagnoses symptomatic UTI. Distinguish ASB definitions, clinical infection criteria, and surveillance definitions.[1][12][29] The EAU 2026 infections guideline uses the same voided-specimen ASB definition (≥10⁵ CFU/mL, confirmed on two consecutive samples in women and one in men), defines CAUTI by ≥10³ CFU/mL in a single catheter or recent-catheter midstream specimen, and gives strong recommendations against routine culture in asymptomatic catheterized patients and against using pyuria, or odorous or cloudy urine, alone to diagnose CAUTI or to separate it from catheter-associated ASB. It gives a weak recommendation to use dipstick testing for acute cystitis and a strong recommendation to culture for suspected systemic UTI, symptoms that persist or recur within four weeks, atypical symptoms, high risk of resistant organisms and pregnancy.[47]

Clinical contextInterpretation
ASB in a voided specimen≥10⁵ CFU/mL without attributable urinary symptoms (IDSA); confirmation in two consecutive specimens for women, one specimen for men. AUA/CUA/SUFU treats bacteriuria of any magnitude without symptoms as ASB
Symptomatic women with pyuria≥10³ CFU/mL of a single uropathogen supports significant bacteriuria; lower counts, including ≥10² CFU/mL of a single plausible uropathogen in selected patients, can be clinically meaningful. Account for contamination and laboratory reporting limits.[29]
Symptomatic catheter-associated infection≥10³ CFU/mL with compatible symptoms and no better explanation supports clinical CAUTI
In-and-out catheter or newly inserted catheterCounts below 10⁵ CFU/mL may represent true bacteriuria; the clinical significance of low counts in an asymptomatic patient is uncertain
Suprapubic or cystoscopically obtained urineLaboratories commonly detect/report to 10³ CFU/mL; discuss lower counts and special processing with the laboratory when clinically relevant

Three or more species often indicate contamination, but genuine polymicrobial bacteriuria can occur with devices or altered anatomy. Correlate culture with symptoms and urinalysis; urinalysis with reflex culture is useful for appropriate patients, while pregnancy screening and selected procedural indications require culture even without a positive inflammatory screen.[1][3][12][29] No urinalysis finding separates cystitis from ASB: pyuria accompanies ASB in about 70% of women with diabetes and 90% of institutionalized older patients.[43] Use urinalysis for its negative predictive value (negative nitrite and leukocyte esterase), and combine it with clinical assessment.[43]

Meares-Stamey Localization (Chronic Bacterial Prostatitis)​

AUA 2025 permits prostate massage and two-glass or four-glass localization testing when the distinction between chronic bacterial prostatitis and CP/CPPS remains uncertain .[49] The four-glass method compares first-void urine (VB1), midstream urine (VB2), expressed prostatic secretions (EPS), and post-massage urine (VB3). Localization of a uropathogen to EPS/VB3, often at a substantially higher count than the premassage specimen, supports a prostatic source.[1][13][14][15]

The two-glass premassage and post-massage test is a practical alternative when EPS is not obtained. In the 353-man NIH cohort comparison, the overall two-glass classification agreed with the four-glass diagnosis in more than 96%. The often-quoted 44–54% sensitivity and 100% specificity describe the VB3 localizing culture alone, and not the overall accuracy of the complete two-glass test.[39]

Do not perform prostatic massage in acute bacterial prostatitis, because of bacteremia risk.[1][14]

Hematuria Workup​

Follow the AUA/SUFU 2025 risk-stratified microhematuria pathway.[9] After the initial evaluation (history including smoking, examination with blood pressure, serum creatinine; directed evaluation for gynecologic or nonmalignant causes), assign a risk stratum from Table 4 of the guideline.[9]

Low/negligibleIntermediateHigh
Criteria to meetAllAny oneAny one
RBC/HPF on a single urinalysis3–1011–25>25
Alternative hematuria criterionNonePreviously low/negligible-risk patient with no prior evaluation and 3–25 RBC/HPF on repeat urinalysisHistory of gross hematuria
Women's age<60 years≥60 yearsNot high risk on age alone
Men's age<40 years40–59 years≥60 years
SmokingNever or <10 pack-years10–30 pack-years>30 pack-years
Other urothelial cancer risk factorsNoneAnyOne or more, plus any high-risk feature
Malignancy risk (guideline estimate)0–0.4%0.2–3.1%1.3–6.3%
EvaluationRepeat urinalysis within 6 months (Statement 10); reclassify if hematuria persists (Statement 11)Cystoscopy and renal ultrasound (Statement 12)Cystoscopy and upper-tract imaging: multiphasic CT urography; MR urography if CT is contraindicated; or, if both are contraindicated, retrograde pyelography plus noncontrast axial imaging or renal ultrasound . See CT Urogram.[9]

Additional urothelial cancer risk factors (guideline Table 3) are irritative lower urinary tract symptoms, prior pelvic radiation, prior cyclophosphamide or ifosfamide, family history of urothelial cancer or Lynch syndrome, occupational benzene or aromatic amine exposure, and a chronic indwelling foreign body. The malignancy estimates were derived under the 2020 age definitions, before the 2025 revision of the age criteria for women.[9]

  • Confirm dipstick blood with microscopy. ≥3 RBCs/HPF defines microhematuria.
  • Visible hematuria in adults warrants prompt urologic assessment even if it resolves.[16][17] Clot retention, hemodynamic instability, or associated systemic illness may require emergency care.[16][17]
  • Cytology or urine markers are not routine substitutes for cystoscopy in low-, negligible- or high-risk microhematuria. For an appropriately counseled intermediate-risk patient who wishes to avoid cystoscopy, cytology or a validated urine marker may help inform that decision; renal/bladder ultrasound is still recommended. If cystoscopy is deferred, repeat urinalysis within 12 months and proceed to cystoscopy for persistent microhematuria.[9]
  • Cytology can be an adjunct in selected high-risk patients with equivocal cystoscopy, or persistent microhematuria and irritative symptoms or CIS risk after a negative evaluation.[9]
  • Anticoagulant or antiplatelet therapy does not remove the need for appropriate evaluation.[9][17]
  • In microhematuria with a family history of renal cell carcinoma, a known genetic renal tumor syndrome, or a personal or family history of or suspicious for Lynch syndrome, obtain upper-tract imaging regardless of risk tier . CT or MR urography or retrograde pyelography is preferred for Lynch syndrome.[9]
  • Women: for hematuria attributed to UTI, repeat microscopic urinalysis after treatment .[9] For an identified gynecologic cause, repeat urinalysis after that cause resolves .[54] Persistent microhematuria warrants risk-based evaluation.[9] The yield is low: an AUGS systematic review of 17 studies (110,179 women) estimated that about 859 women with microhematuria (95% CI 654–1250) need full evaluation to find one urinary-tract malignancy, on limited data.[40] ACOG/AUGS Committee Opinion 703 (2017) advises evaluating asymptomatic, low-risk, never-smoking women aged 35–50 only when they have more than 25 RBC/HPF.[41] AUA/SUFU 2025 defines microhematuria at ≥3 RBC/HPF and places women younger than 60 with 3–10 RBC/HPF and no other risk factors in the low/negligible-risk tier, for whom urinalysis is repeated within six months. Its threshold and risk-tier approach differ from the ACOG/AUGS >25 RBC/HPF evaluation threshold for asymptomatic, low-risk, never-smoking women aged 35–50.[9][41][42] Women tend to present with more advanced bladder cancer, and evaluation guidelines are less consistently followed in women.[42]

Bladder-Cancer Surveillance (Cytology)​

Use the oncology risk category and current surveillance plan.[18][51] AUA/SUO advises against replacing NMIBC surveillance cystoscopy with urinary biomarkers .[51]

  • AUA/SUO 2026 low-risk NMIBC. Routine cytology or urinary biomarkers are not indicated when cystoscopy is normal .[51]
  • AUA/SUO 2026 intermediate- and high-risk NMIBC. As for all NMIBC, the first surveillance cystoscopy follows initial evaluation and treatment within three to four months (Statement 34). After a negative first surveillance cystoscopy, intermediate-risk patients have cystoscopy with cytology every 3–6 months for two years, every 6–12 months in years 3–4, then annually (Statement 38). High-risk patients have cystoscopy with cytology every 3–4 months for two years, every six months in years 3–4, then annually (Statement 39). All three statements are Expert Opinion.[51]
  • EAU 2026 low-risk and intermediate-risk low-grade NMIBC: routine cytology is not recommended, unlike AUA/SUO's inclusion of cytology for intermediate-risk surveillance.[18][51]
  • EAU 2026 high-risk or very-high-risk NMIBC, including intermediate-risk high-grade disease: cystoscopy and cytology at three months, then every three months for two years, every six months until five years, and annually thereafter lifelong.[18]
  • After radical cystectomy: surveillance depends on recurrence risk and the remnant urothelium.[18][33][34] Consider urethral surveillance in selected patients at increased risk.[18][33][34] NCCN advises considering urethral wash cytology every 6–12 months during the first two years, then as clinically indicated, for high-risk patients with a positive urethral margin, multifocal CIS or prostatic urethral invasion (category 2A).[50]

Evidence in diverted patients is limited and cohort-dependent. Chen et al. reported sensitivity 82%, specificity 97%, PPV 75%, and NPV 98% for cytology in the 111 patients with available cytology among a 222-patient cystectomy cohort.[33] Fernández et al. studied 270 patients and found low positive predictive values for both cytology and FISH; almost all detected upper-tract recurrences also had hematuria or abnormal imaging.[33][34]

Urinary Stone Disease: Urinalysis and 24-Hour Urine​

Basic evaluation includes history, serum chemistry, urinalysis, and stone analysis when a stone is available. Obtain culture when infection is suspected and according to procedural requirements.[8][38]

  • Specific metabolic evaluation: offer to high-risk or recurrent stone formers and selected interested first-time stone formers. The AUA recommends one or two 24-hour collections on the usual diet; the EAU specifies two consecutive collections, performed when clinically stable and free of infection.[8][38] Measure volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine, with additional tests dictated by stone type.[8][38]
  • Interpret the complete profile: a large observational analysis found calcium, volume, and citrate contributed most to statistical stone-risk discrimination.[19]
  • Implementation gap: a 2025 Italian primary-care database study of 21,907 adults with stone disease found 4.8% had 24-hour testing and 0.6% had all three studied measurements (calcium, oxalate, citrate).[35]
  • Primary hyperparathyroidism: obtain serum calcium as part of evaluation and intact PTH when PHPT is suspected, including high or high-normal calcium in the appropriate setting.[8][36]

Urinary Diversions and Augmented Bladders​

Bowel-based urinary reconstructions commonly produce baseline pyuria, microscopic blood, and bacteriuria. Distinguish these findings from a new symptomatic infection.[20][21]

  • In Magistro et al.'s 429-patient retrospective cystectomy cohort, tested patients had positive urinalysis and cultures by 12 months; polymicrobial cultures were more frequent in neobladders than conduits (81.3% versus 67.2%).[20] A 26-study systematic review found reported bacteriuria prevalence ranging from 9.1% to 100%.[20][21]
  • Do not give antibiotics for bacteriuria alone. Evaluate new compatible local, systemic, or population-specific atypical symptoms, obtain an appropriate culture, and consider obstruction or other causes. Pregnancy and procedures with mucosal trauma remain distinct ASB-treatment indications.[12][20][21]
  • Hydronephrosis was associated with infectious complications in the cohort (OR 4.2, 95% CI 1.5–11.6). Investigate its cause; infection with obstruction requires urgent assessment.[20]
  • Long-term antibiotics do not reliably eradicate diversion colonization. This differs from an individualized prevention decision for documented recurrent symptomatic infections.[21]
  • Continue lifelong renal, metabolic, and anatomic follow-up. In adults with NLUTD and bowel reconstruction, AUA/SUFU specifies annual focused assessment, basic metabolic testing, and urinary-tract imaging; tailor follow-up in other reconstruction populations.[22]

Neurogenic Bladder and Clean Intermittent Catheterization​

ASB is common with CIC and chronic catheterization. AUA/SUFU advises against surveillance urine testing, including culture, in asymptomatic NLUTD patients (Statement 23) and against treating ASB (Statement 24), both Moderate Recommendations, Grade C. Avoid routine surveillance cultures and ASB treatment, apart from a separate established indication such as pregnancy or an upcoming procedure with mucosal trauma.[12][22][23]

Obtain urinalysis and culture when new signs or symptoms suggest infection. In SCI these may include changes in continence, spasticity, malaise, or autonomic dysreflexia as well as typical urinary symptoms; exclude other causes. A catheter-associated clinical infection definition uses ≥10³ CFU/mL with compatible symptoms and no better source. Culture results alone, cloudy urine alone, or pyuria alone are insufficient.[12][23] In a cohort of 381 symptomatic UTI episodes in 209 male SCI patients using intermittent catheterization, the most prevalent signs, alone or in combination, were cloudy or malodorous urine (51.4%), new urinary incontinence (51.2%), fatigue (41.7%), fever (30.7%), and increased spasticity (30.2%); about a third of episodes involved only one sign, and in patients presenting with an isolated sign, urine colony counts and white-cell counts did not differ significantly from asymptomatic controls.[48]

Perioperative Urine Testing​

Assess for active infection and choose testing and antimicrobial prophylaxis according to the procedure and patient risk.[3] For urethroplasty, the EAU 2026 guideline describes obtaining a urine culture one to two weeks before surgery to guide treatment of infection or colonization, and strongly recommends intraoperative prophylaxis.[52]

  • Endoscopic procedures with mucosal trauma: IDSA recommends screening for and treating ASB before these procedures . It suggests a preoperative culture with targeted rather than empiric therapy (weak, very low-quality evidence) and a short course of 1 or 2 doses started 30 to 60 minutes before the procedure (weak, low-quality evidence). The AUA best practice statement reaches the same practical end by giving standard single-dose prophylaxis regardless of ASB and using a culture obtained before the procedure to choose the agent when infection is suspected or risk is higher. This indication is distinct from routine screening of asymptomatic catheter or diversion patients.[3][12]
  • Asymptomatic candiduria before urologic manipulation: IDSA recommends oral fluconazole 400 mg (6 mg/kg) daily or amphotericin B deoxycholate 0.3–0.6 mg/kg daily for several days before and after the procedure . Remove an indwelling bladder catheter when feasible .[53]
  • AUS or penile-prosthesis implantation: IDSA suggests not screening for or treating ASB specifically for implantation ; standard perioperative prophylaxis remains indicated.[12]
  • Midurethral sling: a 661-patient retrospective study did not find significantly fewer postoperative UTIs with preoperative culture screening in asymptomatic women. A systematic review also found no clear benefit from routine postoperative nitrofurantoin in the studied catheterized populations; neither finding removes procedure-appropriate perioperative prophylaxis. In a placebo-controlled RCT of daily nitrofurantoin during short-term transurethral catheterization after pelvic reconstructive surgery (n = 159), UTI treatment within 3 weeks was 22% with nitrofurantoin versus 13% with placebo (RR 1.73, 95% CI 0.85–3.52); the AUGS 2025 consensus notes suprapubic catheterization as the exception in older data.[26][27][43][46]
  • Urogynecologic surgery (day-of-surgery bacteriuria): in a matched analysis, 9.5% of women had a positive day-of-surgery catheterized culture, and these women had more postoperative UTIs despite standard prophylaxis (29.6% versus 5.6%; OR 7.2), with no pyelonephritis or urosepsis in either group.[44] In a decision model, screening only women with a history of rUTI was cost-effective at base-case costs (sensitive to culture cost), and universal screening was dominated; the absolute difference in postoperative UTI was under 1 percentage point.[44][45]
  • Active symptomatic UTI: defer elective intervention until appropriately treated and symptoms resolve, accounting for situations where urgent drainage or source control is itself needed.[3]

Recurrent UTI in Women (Urogynecologic Perspective)​

For the usual uncomplicated rUTI population, document symptoms together with pyuria and a uropathogen during symptomatic episodes; do not establish a recurrent bacterial diagnosis from symptoms alone or from one remote culture. The 2025 AUA/CUA/SUFU guideline recommends obtaining urinalysis and a urine specimen for culture and susceptibility testing before treating each symptomatic acute cystitis episode .[29] Selected rUTI patients may use patient-initiated treatment while awaiting culture results .[28][29]

A lower colony count may be significant in a carefully selected symptomatic patient with pyuria. If symptoms repeatedly fail to correlate with inflammation and a plausible organism, reassess the diagnosis rather than repeatedly escalating antibiotics. Cystoscopy and upper-tract imaging are not routine in the uncomplicated index patient but may be appropriate with complicating features.[1][29]

Do not perform surveillance cultures or treat ASB solely because a woman has a history of rUTI.[12][24][25][29]

Expanded Quantitative Urine Culture (EQUC) and Emerging Technologies​

EQUC uses larger inocula and additional growth conditions to recover organisms missed by standard culture. In Price et al.'s 150-woman study, standard culture missed 67% of organisms detected by expanded culture; this is not equivalent to “67% more detected.” A streamlined protocol detected 84% versus 33% with standard culture.[30]

In the 225-participant Barnes randomized trial, symptom resolution at 7–10 days was 64% with standard-culture-directed care versus 69% with EQUC-directed care (p=0.46; outcome data in 215 participants). A secondary symptom-score difference favored EQUC.[37]

IDSA/ASM 2024 does not support routine expanded culture across all populations.[1] Molecular and sequencing methods can also detect colonizing organisms; a positive result is not, by itself, an indication for antibiotics. Reviews discuss possible selected applications, but clinical utility and treatment thresholds remain uncertain, particularly for chronic nonspecific LUTS or incontinence.[1][31][32]

The AUGS 2025 consensus statement (Q20–Q21) finds insufficient evidence that extended cultures or molecular testing improve management in women with urinary symptoms, and warns of overtreatment: 21 of 22 controls in the one randomized comparison had positive sequencing results. These tests cannot distinguish UTI from ASB, and fastidious organisms found only on molecular testing should not be treated without compatible symptoms. No biomarker such as interleukin-6 is clinically available to separate ASB from UTI.[43]

Asymptomatic Bacteriuria: When to Screen and Treat​

The principal established indications in the 2019 IDSA guideline are pregnancy (culture at an early prenatal visit) and endoscopic urologic procedures with anticipated mucosal trauma. The absence of symptoms is needed by the ASB definition.[12]

Routine treatment is not recommended for older adults, diabetes, SCI, chronic urinary catheters, elective nonurologic surgery, renal transplant recipients beyond the first month, or nonrenal solid-organ transplant recipients without a separate indication. Some settings remain evidence gaps, including the first month after renal transplantation (where AUGS 2025 favors treatment within 2 months, whereas EAU 2026 advises against treatment in renal transplant recipients) and high-risk neutropenia; avoid converting a simplified “two indications” rule into a claim that every special population has settled evidence.[12][24][25][43][47]

Key Takeaways​

  • Interpret symptoms, anatomy, specimen quality, urinalysis, and culture together.
  • Mixed growth often reflects contamination; devices and diversions can also produce genuine polymicrobial bacteriuria.
  • Bacteriuria alone does not require antibiotics. A diversion patient can have a symptomatic infection without fever or other systemic signs.
  • Confirm dipstick blood with microscopy and follow the current risk-stratified hematuria pathway.
  • Keep ASB treatment, perioperative prophylaxis, and treatment of active infection distinct.

See Also​

References​

1. Miller JM, Binnicker MJ, Campbell S, et al. "Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)." Clinical Infectious Diseases. 2024;ciae104. doi:10.1093/cid/ciae104

2. LaRocco MT, Franek J, Leibach EK, et al. "Effectiveness of Preanalytic Practices on Contamination and Diagnostic Accuracy of Urine Cultures: A Laboratory Medicine Best Practices Systematic Review and Meta-Analysis." Clinical Microbiology Reviews. 2016;29(1):105–47. doi:10.1128/CMR.00030-15

3. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. "Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis." Journal of Urology. 2020;203(2):351–356. doi:10.1097/JU.0000000000000509

4. Hitzeman N, Greer D, Carpio E. "Office-Based Urinalysis: A Comprehensive Review." American Family Physician. 2022;106(1):27–35B. PMID 35839369

5. Chu CM, Lowder JL. "Diagnosis and Treatment of Urinary Tract Infections across Age Groups." American Journal of Obstetrics and Gynecology. 2018;219(1):40–51. doi:10.1016/j.ajog.2017.12.231

6. Schaeffer AJ, Nicolle LE. "Urinary Tract Infections in Older Men." New England Journal of Medicine. 2016;374(6):562–71. doi:10.1056/NEJMcp1503950

7. Ingelfinger JR. "Hematuria in Adults." New England Journal of Medicine. 2021;385(2):153–163. doi:10.1056/NEJMra1604481

8. Pearle MS, Goldfarb DS, Assimos DG, et al. "Medical Management of Kidney Stones: AUA Guideline." Journal of Urology. 2014;192(2):316–24. doi:10.1016/j.juro.2014.05.006

9. Barocas DA, Lotan Y, Matulewicz RS, et al. "Updates to Microhematuria: AUA/SUFU Guideline (2025)." Journal of Urology. 2025;213(5):547–557. doi:10.1097/JU.0000000000004490

10. Hernandez JD, Ellison JS, Lendvay TS. "Current Trends, Evaluation, and Management of Pediatric Nephrolithiasis." JAMA Pediatrics. 2015;169(10):964–70. doi:10.1001/jamapediatrics.2015.1419

11. Coe FL, Parks JH, Asplin JR. "The Pathogenesis and Treatment of Kidney Stones." New England Journal of Medicine. 1992;327(16):1141–52. doi:10.1056/NEJM199210153271607

12. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America." Clinical Infectious Diseases. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

13. Lam JC, Stokes W. "Acute and Chronic Prostatitis." American Family Physician. 2024;110(1):45–51. PMID 39028781

14. Kulkarni PA, Cortés-Penfield NW, Brehm TJ, et al. "State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis." Clinical Infectious Diseases. 2026;82(1):1–13. doi:10.1093/cid/ciaf483

15. Borgert BJ, Wallen EM, Pham MN. "Prostatitis." JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

16. Lenis AT, Lec PM, Chamie K. "Bladder Cancer: A Review." JAMA. 2020;324(19):1980–1991. doi:10.1001/jama.2020.17598

17. Nielsen M, Qaseem A. "Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians." Annals of Internal Medicine. 2016;164(7):488–97. doi:10.7326/M15-1496

18. European Association of Urology. "Non-muscle-invasive Bladder Cancer: Follow-up of Patients with NMIBC." 2026. Guideline

19. Ferraro PM, Taylor EN, Curhan GC. "24-Hour Urinary Chemistries and Kidney Stone Risk." American Journal of Kidney Diseases. 2024;84(2):164–169. doi:10.1053/j.ajkd.2024.02.010

20. Magistro G, Zimmermann L, Bischoff R, et al. "The Natural Course of Urinalysis After Urinary Diversion." World Journal of Urology. 2021;39(5):1559–1567. doi:10.1007/s00345-020-03355-0

21. Qu LG, Adam A, Ranasinghe W, Lawrentschuk N. "Systematic Review: Bacterial Colonisation of Conduits and Neobladders — When to Test, Watch, and Treat." World Journal of Urology. 2020;38(6):1413–1422. doi:10.1007/s00345-019-02964-8

22. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." Journal of Urology. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

23. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation." Journal of Urology. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

24. Luu T, Albarillo FS. "Asymptomatic Bacteriuria: Prevalence, Diagnosis, Management, and Current Antimicrobial Stewardship Implementations." American Journal of Medicine. 2022;135(8):e236–e244. doi:10.1016/j.amjmed.2022.03.015

25. Colgan R, Jaffe GA, Nicolle LE. "Asymptomatic Bacteriuria." American Family Physician. 2020;102(2):99–104.

26. Laus K, Eng S, Nguyen JN. "Impact of Preoperative Urinary Tract Infection Screening in Asymptomatic Women Undergoing Midurethral Sling." International Urogynecology Journal. 2024;35(2):423–430. doi:10.1007/s00192-023-05716-w

27. Sanaee MS, Hutcheon JA, Larouche M, et al. "Urinary Tract Infection Prevention After Midurethral Slings in Pelvic Floor Reconstructive Surgery: A Systematic Review and Meta-Analysis." Acta Obstetricia et Gynecologica Scandinavica. 2019;98(12):1514–1522. doi:10.1111/aogs.13661

28. Advani SD, Thaden JT, Perez R, et al. "State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women." Clinical Infectious Diseases. 2025;80(3):e31–e42. doi:10.1093/cid/ciae653

29. AUA/CUA/SUFU. "Recurrent Uncomplicated Urinary Tract Infections in Women." Amended 2025. Full guideline

30. Price TK, Dune T, Hilt EE, et al. "The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms." Journal of Clinical Microbiology. 2016;54(5):1216–22. doi:10.1128/JCM.00044-16

31. Gasiorek M, Hsieh MH, Forster CS. "Utility of DNA Next-Generation Sequencing and Expanded Quantitative Urine Culture in Diagnosis and Management of Chronic or Persistent Lower Urinary Tract Symptoms." Journal of Clinical Microbiology. 2019;58(1):e00204-19. doi:10.1128/JCM.00204-19

32. Deen NS, Ahmed A, Tasnim NT, Khan N. "Clinical Relevance of Expanded Quantitative Urine Culture in Health and Disease." Frontiers in Cellular and Infection Microbiology. 2023;13:1210161. doi:10.3389/fcimb.2023.1210161

33. Chen H, et al. "Urine Cytology in Monitoring Recurrence in Urothelial Carcinoma After Radical Cystectomy and Urinary Diversion." Cancer Cytopathology. 2016;124(4):273–8. doi:10.1002/cncy.21650

34. Fernández MI, et al. "The Role of FISH and Cytology in Upper Urinary Tract Surveillance After Radical Cystectomy for Bladder Cancer." Urologic Oncology. 2012;30(6):821–4. doi:10.1016/j.urolonc.2010.08.006

35. Ferraro PM, Spasiano A, Gambaro G, et al. "24-H Urine Test Application in Patients With Kidney Stone Disease: A Population-Based Study in a Primary Care Setting." Journal of Nephrology. 2025. doi:10.1007/s40620-025-02389-0

36. Lui MS, Fisher JC, Underwood HJ, Patel KN, Ogilvie JB. "Stones Left Unturned: Missed Opportunities to Diagnose Primary Hyperparathyroidism in Patients With Nephrolithiasis." Surgery. 2022;171(1):23–28. doi:10.1016/j.surg.2021.03.073

37. Barnes HC, Wolff B, Abdul-Rahim O, et al. "A Randomized Clinical Trial of Standard versus Expanded Cultures to Diagnose Urinary Tract Infections in Women." Journal of Urology. 2021;206(5):1212–1221. doi:10.1097/JU.0000000000001949

38. European Association of Urology. "Urolithiasis: Metabolic Evaluation and Recurrence Prevention." 2026. Guideline

39. Nickel JC, Shoskes D, Wang Y, et al. "How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome?" Journal of Urology. 2006;176(1):119–124. doi:10.1016/S0022-5347(06)00498-8

40. Jeppson PC, Jakus-Waldman S, Yazdany T, et al. "Microscopic Hematuria as a Screening Tool for Urologic Malignancies in Women." Female Pelvic Med Reconstr Surg. 2021;27(1):9–15. doi:10.1097/SPV.0000000000000726

41. American College of Obstetricians and Gynecologists; American Urogynecologic Society. "Committee Opinion No. 703: Asymptomatic Microscopic Hematuria in Women." Obstet Gynecol. 2017;129(6):e168–e172. doi:10.1097/AOG.0000000000002059

42. Asfaw TS, Rickey LM, Jeppson PC. "Risk-Stratified Evaluation of Asymptomatic Microscopic Hematuria in Women: Clinical Implications of New Guidelines." Urogynecology (Phila). 2026;32(6):567–568. doi:10.1097/SPV.0000000000001838

43. Siddiqui NY, Ackerman AL, Advani SD, et al. "Management of Asymptomatic Bacteriuria in Adult Female Populations." Urogynecology (Phila). 2025;31(9):827–845. doi:10.1097/SPV.0000000000001731

44. Fok CS, McKinley K, Mueller ER, et al. "Day of Surgery Urine Cultures Identify Urogynecologic Patients at Increased Risk for Postoperative Urinary Tract Infection." J Urol. 2013;189(5):1721–1724. doi:10.1016/j.juro.2012.11.167

45. Hendrickson WK, Havrilesky L, Siddiqui NY. "Cost-Effectiveness of Bacteriuria Screening Before Urogynecologic Surgery." Am J Obstet Gynecol. 2022;226(6):831.e1–831.e12. doi:10.1016/j.ajog.2021.11.1375

46. Dieter AA, Amundsen CL, Edenfield AL, et al. "Oral Antibiotics to Prevent Postoperative Urinary Tract Infection: A Randomized Controlled Trial." Obstet Gynecol. 2014;123(1):96–103. doi:10.1097/AOG.0000000000000024

47. European Association of Urology. EAU Guidelines on Urological Infections (sections 3.3, 3.4.3 and 3.8.3). 2026 limited update, March 2026. Full guideline.

48. Ronco E, Denys P, Bernède-Bauduin C, et al. "Diagnostic criteria of urinary tract infection in male patients with spinal cord injury." Neurorehabil Neural Repair. 2011;25(4):351-358. doi:10.1177/1545968310383432

49. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach. J Urol. 2025;214(2):116-126. doi:10.1097/JU.0000000000004564 Full 2025 guideline

50. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2026. August 6, 2026. BL-E 3–4 of 6, footnote f; Discussion MS-28. Guideline.

51. Clark PE, Holzbeierlein J, Chang SS, et al. 2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. Published online September 4, 2026. doi:10.1097/JU.0000000000005280. Corresponding AUA/SUO full guideline, approved August 2026; Statements 9–10, 34 and 38–39.

52. European Association of Urology. EAU Guidelines on Urethral Strictures: Perioperative Care of Urethral Surgery. 2026 limited update. Full guideline.

53. Pappas PG, Kauffman CA, Andes DR, et al. "Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America." Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933

54. Barocas DA, Boorjian SA, Alvarez RD, et al. "Microhematuria: AUA/SUFU Guideline." J Urol. 2020;204(4):778-786. doi:10.1097/JU.0000000000001297